Company Overview and News


Add SANNV
to your dashboard

Headline News

Exclusive: Makers took big price increases on widely used U.S. drugs | Reuters

2016-04-04 reuters
NEW YORK Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found.

Exclusive: Makers took big price increases on widely used U.S. drugs - Business Insider

2016-04-04 businessinsider
NEW YORK (Reuters) - Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found.

Why MannKind Will Continue To Slide Toward A Bankruptcy Filing

2016-04-04 seekingalpha
With substantial debt obligations over the next few years, it is unclear how the company will become cash flow positive.

Exclusive: Makers took big price increases on widely used US drugs

2016-04-04 channelnewsasia
NEW YORK: Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found.

Regeneron Pharmaceuticals Is My Top Pick In The Biotech Space

2016-04-02 seekingalpha
The shares have sold off in sympathy with the meltdown in the biotech sector, with one caveat that REGN has the best near-term pipeline in the business.

Why Fitbit Inc (FIT), Medivation Inc (MDVN) and Tesla Motors Inc (TSLA) Are 3 of Today’s Best Stocks

2016-04-01 investorplace
U.S. stocks limped into the end of the first quarter with modest losses Thursday as the S&P 500 lost 0.2% while the Dow Jones Industrial Average gave up 0.18%. The Nasdaq Composite was able to cobble together a small gain on the day.

The Top 100 Manufacturers Of Generic Pharmaceuticals Worldwide

2016-03-31 prnewswire
NEW YORK, March 31, 2016 /PRNewswire/ -- Did you know? - Zentiva, the generics business of the Sanofi Group, employs 6,000 people worldwide. - Jeff Watson is President, Global Generics at Apotex, the largest Canadian-owned pharmaceutical company. - Željko Dudi? is Director of Purchasing at Hemofarm, the leading generic pharmaceutical company in Serbia. - Beximco Pharmaceuticals, a leading manufacturer and exporter of medicines in Bangladesh, currently produces more than 300 generic medicines which are available in well over 500 different presentations.

Patent Troubles Hit Biogen After Gilead, Regeneron; What���s Next?

2016-03-24 bidnessetc
Some of the major US biotech companies are currently embroiled in high-profile patent disputes, which have put revenue from their best-selling products at risk. A new patent decision crops up every other day, emphasizing the treacherous and murky nature of pharma patent law.

Amgen PCSK9 Suit: Regeneron���s Praluent Can be Pulled Off US Market

2016-03-23 bidnessetc
Last week, Amgen, Inc. (NASDAQ:AMGN) won a patent dispute against Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and development partner Sanofi SA (ADR) (NYSE:SNY) over the cholesterol-lowering drug class, PCSK-9 inhibitors. The conflicting parties scored approval for their respective PCSK9 drugs, Repatha and Praluent, within a month of each other last summer and have been fighting for market share ever since.

TIMELINE-Shakeup at Valeant as longtime CEO Pearson leaving

2016-03-21 reuters
March 21 Valeant Pharmaceuticals International Inc , target of a securities investigation and under scrutiny for its pricing and accounting practices, said on Monday that its longtime chief executive officer was leaving just three weeks after returning from a medical leave.

Amgen, Inc.: AMGN Stock Looking to Break Out

2016-03-18 investorplace
While the S&P 500 continues to rally to new highs for the year, biotech stocks continue to languish.

How Amgen Inc���s PCSK9 Patent Win can Play Out for Regeneron Pharmaceuticals Inc

2016-03-17 bidnessetc
Amgen, Inc. (NASDAQ:AMGN) scored its first victory, related to its patent infringement claim against Regeneron and development partner Sanofi, on Wednesday. A federal jury supported the validity of two Amgen patents associated with its newly launched cholesterol-lowering drug, Repatha. In October 2014, Amgen had launched a lawsuit against Regeneron/Sanofi to stop them from selling a rival drug, Praluent, on grounds that it infringed upon Repatha’s patents.

Relypsa Inc (RLYP) Attractive Despite Less-Than-Rapid Veltassa Uptake

2016-03-17 bidnessetc
Relypsa Inc. (NASDAQ:RLYP) dropped as low as 10% in yesterday’s trade, and closed down 6.65% at $12.08. The decline followed the biotech’s SEC filing, which reported prescription data of its newly launched star drug, Veltassa, for the month of February. The stock has plunged nearly 16% in the past two days, compared to a 4.3% loss of the iShares NASDAQ Biotechnology Index (IBB).

US-made dengue vaccine 100 pct effective

2016-03-17 newshub.co.nz
A dengue vaccine developed by US National Institutes of Health scientists protected everyone given the shot against the virus in a promising small study published on Wednesday.

UPDATE 2-Amgen beats Sanofi, Regeneron at cholesterol drug trial

2016-03-16 reuters
A federal jury ruled in favor of Amgen Inc in its lawsuit accusing Sanofi SA and Regeneron Pharmaceuticals Inc of infringing patents for antibodies related to a cholesterol drug, the defendants said on Wednesday.